Drugs / 7vPnC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00444457 Comparator | May 2007 → Jun 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00384059 Comparator | Oct 2006 → Oct 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 7vPnC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00384059 ↗ |
| Known as | PCV7 | “The 7-valent pneumococcal conjugate vaccine (PCV7; serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) has decreased invasive pneumococcal disease incidence.” PMID 23584582 ↗ Aug 20131“The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses” PMID 23965217 ↗ Aug 2013 |
| Modality | Vaccine | “The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses” PMID 23965217 ↗ Aug 2013 |
| Route | Intramuscular | “0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.” NCT00444457 ↗ |